UBS Group
INO icon

UBS Group’s Inovio Pharmaceuticals INO Stock Holding History

UBS Group’s Portfolio INO Stock Details INO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$434K Buy
249,650
+79,071
+46% +$130K ﹤0.01% 6179
2025
Q4 		$297K Sell
170,579
-122,483
-42% -$270K ﹤0.01% 6366
2025
Q3 		$686K Buy
293,062
+93,383
+47% +$179K ﹤0.01% 5855
2025
Q2 		$406K Sell
199,679
-8,188
-4% -$15.7K ﹤0.01% 6184
2025
Q1 		$339K Buy
207,867
+30,893
+17% +$62K ﹤0.01% 6149
2024
Q4 		$324K Buy
176,974
+163,259
+1,190% +$723K ﹤0.01% 6150
2024
Q3 		$79.3K Sell
13,715
-13,676
-50% -$113K ﹤0.01% 6515
2024
Q2 		$221K Buy
27,391
+25,475
+1,330% +$268K ﹤0.01% 5590
2024
Q1 		$26.6K Sell
1,916
-2,457
-56% -$21.2K ﹤0.01% 6787
2023
Q4 		$26.8K Sell
4,373
-220
-5% -$1.09K ﹤0.01% 6920
2023
Q3 		$21.4K Buy
4,593
+4,000
+675% +$22.1K ﹤0.01% 6767
2023
Q2 		$3.18K Sell
593
-66,000
-99% -$532K ﹤0.01% 7657
2023
Q1 		$655K Sell
66,593
-9,794
-13% -$167K ﹤0.01% 4484
2022
Q4 		$1.43M Buy
76,387
+51,168
+203% +$1.16M ﹤0.01% 3726
2022
Q3 		$522K Sell
25,219
-25,135
-50% -$643K ﹤0.01% 4296
2022
Q2 		$1.05M Sell
50,354
-86,314
-63% -$2.43M ﹤0.01% 3702
2022
Q1 		$5.89M Buy
136,668
+68,108
+99% +$3.07M ﹤0.01% 2383
2021
Q4 		$4.11M Buy
68,560
+30,465
+80% +$2.44M ﹤0.01% 3040
2021
Q3 		$3.27M Buy
38,095
+30,070
+375% +$3.02M ﹤0.01% 3127
2021
Q2 		$892K Sell
8,025
-978
-11% -$93.9K ﹤0.01% 4273
2021
Q1 		$1M Buy
9,003
+4,227
+89% +$556K ﹤0.01% 4241
2020
Q4 		$507K Buy
4,776
+264
+6% +$35.1K ﹤0.01% 4591
2020
Q3 		$628K Buy
4,512
+277
+7% +$57.8K ﹤0.01% 3993
2020
Q2 		$1.37M Buy
4,235
+1,472
+53% +$236K ﹤0.01% 3232
2020
Q1 		$246K Sell
2,763
-7,802
-74% -$481K ﹤0.01% 4562
2019
Q4 		$419K Buy
10,565
+4,440
+72% +$134K ﹤0.01% 4995
2019
Q3 		$151K Buy
6,125
+4,704
+331% +$143K ﹤0.01% 5461
2019
Q2 		$50K Sell
1,421
-21,893
-94% -$870K ﹤0.01% 5929
2019
Q1 		$1.04M Sell
23,314
-19,123
-45% -$964K ﹤0.01% 3547
2018
Q4 		$2.04M Buy
42,437
+19,664
+86% +$1.19M ﹤0.01% 3022
2018
Q3 		$1.52M Sell
22,773
-1,174
-5% -$65.4K ﹤0.01% 3465
2018
Q2 		$1.13M Sell
23,947
-12,961
-35% -$715K ﹤0.01% 3682
2018
Q1 		$2.09M Buy
36,908
+22,531
+157% +$1.22M ﹤0.01% 3104
2017
Q4 		$713K Sell
14,377
-10,747
-43% -$666K ﹤0.01% 4037
2017
Q3 		$1.91M Buy
25,124
+10,173
+68% +$757K ﹤0.01% 3166
2017
Q2 		$1.41M Buy
14,951
+1,500
+11% +$128K ﹤0.01% 3324
2017
Q1 		$1.07M Sell
13,451
-8,196
-38% -$653K ﹤0.01% 3475
2016
Q4 		$1.8M Buy
21,647
+4,880
+29% +$441K ﹤0.01% 3007
2016
Q3 		$1.88M Sell
16,767
-26
-0.2% -$2.87K ﹤0.01% 2898
2016
Q2 		$1.86M Buy
16,793
+5,722
+52% +$695K ﹤0.01% 2829
2016
Q1 		$1.16M Sell
11,071
-1,658
-13% -$128K ﹤0.01% 3127
2015
Q4 		$1.03M Buy
12,729
+837
+7% +$66.6K ﹤0.01% 3389
2015
Q3 		$825K Buy
11,892
+1,421
+14% +$124K ﹤0.01% 3532
2015
Q2 		$1.02M Buy
10,471
+946
+10% +$101K ﹤0.01% 3547
2015
Q1 		$933K Sell
9,525
-4,384
-32% -$425K ﹤0.01% 3634
2014
Q4 		$1.53M Buy
+13,909
New +$1.7M ﹤0.01% 3161

Other funds holding INO

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS Group's INO Position: Q1 2026 in Review

UBS Group increased its Inovio Pharmaceuticals (INO) stake by 46% in Q1 2026, buying an estimated $130K and bringing the position to 249,650 shares worth $434K. The position accounts for ﹤0.01% of the portfolio, ranked #6179.

UBS Group first reported a position in INO in Q4 2014 and has held it in 46 quarters since. The position peaked at $5.89M in Q1 2022. 100 funds tracked by Wall St. Rank hold INO as of Q1 2026.

  • UBS Group held 249,650 shares of Inovio Pharmaceuticals worth $434K as of Q1 2026.
  • UBS Group bought 79,071 Inovio Pharmaceuticals shares in Q1 2026, an estimated $130K.
  • Inovio Pharmaceuticals made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6179 holding.
  • UBS Group first reported a position in Inovio Pharmaceuticals in Q4 2014 and has held it in 46 quarters since.
  • UBS Group's Inovio Pharmaceuticals position peaked at $5.89M in Q1 2022.
  • 100 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.